Eraxis is active against most clinically applicable species of Candida. Eraxis also has activity against Aspergillus spp. In-vitro data show that Eraxis is active against fluconazole-resistant Candida.

Two trials evaluated Eraxis (anidulafungin) for treatment of candidemia and other candida infections. One was a dose-ranging study comparing anidulafungin 50mg, 75mg and 100mg once daily and the other compared anidulafungin 100mg once daily to fluconazole 400mg IV once per day. In the dose-ranging study, the primary outcome was global response in the evaluable patients, at the follow-up visit, which took place 2- weeks after the close of therapy. The global response rate at follow-up was similar for the 75 and 100mg doses (90% and 89%) in comparison with a lower response rate with seen with the 50mg dose (72%).